Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

6.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8-specific signature.

Blood·2023
Same author

Mutational Profile and Pathological Features of a Case of Interleukin-10 and RGS1-Positive Spindle Cell Variant Diffuse Large B-Cell Lymphoma.

Hematology reports·2023
Same author

Correction to: Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation.

Virchows Archiv : an international journal of pathology·2023
Same author

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Leukemia·2023
Same author

Advances in the Classification of Myeloid and Lymphoid Neoplasms.

Virchows Archiv : an international journal of pathology·2022
Same author

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Leukemia·2022
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K

MYC alterations in diffuse large B-cell lymphomas.

Kennosuke Karube1, Elias Campo1

  • 1Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Seminars in Hematology
|March 26, 2015
PubMed
Summary
This summary is machine-generated.

MYC gene alterations in diffuse large B-cell lymphoma (DLBCL) are linked to aggressive disease. Co-expression of MYC and BCL2 proteins also indicates a poor prognosis, highlighting the need for diagnostic strategies.

More Related Videos

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941

Related Experiment Videos

Last Updated: Apr 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • MYC is a critical transcription factor with oncogenic potential, tightly regulated in normal lymphoid cells.
  • MYC expression is normally repressed by BCL6 and BLIMP1 in germinal center B and plasma cells, respectively.
  • Lymphomas with MYC alterations often arise from MYC-negative cells, requiring additional oncogenic events.

Purpose of the Study:

  • To investigate the prevalence and clinical implications of MYC genetic alterations in diffuse large B-cell lymphoma (DLBCL).
  • To examine the association of MYC alterations with BCL2 or BCL6 rearrangements and their impact on patient prognosis.
  • To evaluate the prognostic significance of MYC and BCL2 protein coexpression in DLBCL.

Main Methods:

  • Analysis of MYC rearrangements and amplifications in DLBCL patient samples.
  • Assessment of concurrent BCL2 or BCL6 rearrangements.
  • Evaluation of MYC and BCL2 protein coexpression via immunohistochemistry.
  • Correlation of genetic alterations and protein expression with clinical outcomes.

Main Results:

  • MYC rearrangements or amplifications occur in 5-14% of DLBCL, often alongside BCL2 or BCL6 alterations.
  • Concurrent MYC and BCL2/BCL6 genetic alterations are associated with aggressive disease and poor patient outcomes.
  • MYC and BCL2 protein coexpression, independent of genetic alterations, also confers a poor prognosis.
  • Tumor behavior can be modulated by factors like MYC translocation partners and protein expression levels.

Conclusions:

  • MYC aberrations are significant drivers in a subset of DLBCL, contributing to aggressive clinical behavior.
  • Combined genetic hits (MYC with BCL2/BCL6) and protein coexpression (MYC/BCL2) represent critical poor prognostic factors in DLBCL.
  • Further research is essential to refine diagnostic strategies for identifying MYC aberrations and guiding clinical management in DLBCL.